422 related articles for article (PubMed ID: 29159965)
1. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
2. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
3. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
4. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
5. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
6. Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Farr AM; Johnston SS; Ritchings C; Brouillette M; Rosenblatt L
J Med Econ; 2016; 19(4):386-96. PubMed ID: 26640980
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Aberg JA; Tebas P; Overton ET; Gupta SK; Sax PE; Landay A; Falcon R; Ryan R; De La Rosa G
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1184-95. PubMed ID: 22352336
[TBL] [Abstract][Full Text] [Related]
8. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Ryom L; Lundgren JD; El-Sadr W; Reiss P; Kirk O; Law M; Phillips A; Weber R; Fontas E; d' Arminio Monforte A; De Wit S; Dabis F; Hatleberg CI; Sabin C; Mocroft A;
Lancet HIV; 2018 Jun; 5(6):e291-e300. PubMed ID: 29731407
[TBL] [Abstract][Full Text] [Related]
10. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
[TBL] [Abstract][Full Text] [Related]
11. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Maggi P; Bellacosa C; Leone A; Volpe A; Ricci ED; Ladisa N; Cicalini S; Grilli E; Viglietti R; Chirianni A; Bellazzi LI; Maserati R; Martinelli C; Corsi P; Celesia BM; Sozio F; Angarano G
Atherosclerosis; 2017 Aug; 263():398-404. PubMed ID: 28522147
[TBL] [Abstract][Full Text] [Related]
13. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Ofotokun I; Na LH; Landovitz RJ; Ribaudo HJ; McComsey GA; Godfrey C; Aweeka F; Cohn SE; Sagar M; Kuritzkes DR; Brown TT; Patterson KB; Para MF; Leavitt RY; Villasis-Keever A; Baugh BP; Lennox JL; Currier JS;
Clin Infect Dis; 2015 Jun; 60(12):1842-51. PubMed ID: 25767256
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
[TBL] [Abstract][Full Text] [Related]
16. Effect of darunavir on lipid profile in HIV-infected patients.
Overton ET; Arathoon E; Baraldi E; Tomaka F
HIV Clin Trials; 2012; 13(5):256-70. PubMed ID: 23134626
[TBL] [Abstract][Full Text] [Related]
17. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Adrian S; Miao H; Feng H; Scherzinger A; Nardini G; Beghetto B; Roncaglia E; Ligabue G; Milic J; Guaraldi G; Lake JE; Erlandson KM
HIV Res Clin Pract; 2020 Aug; 21(4):91-98. PubMed ID: 32878571
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Menshawy A; Ismail A; Abushouk AI; Ahmed H; Menshawy E; Elmaraezy A; Gadelkarim M; Abdel-Maboud M; Attia A; Negida A
Arch Virol; 2017 Aug; 162(8):2181-2190. PubMed ID: 28361290
[TBL] [Abstract][Full Text] [Related]
19. Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
Antivir Ther; 2016; 21(4):353-8. PubMed ID: 26561496
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Borghetti A; Lombardi F; Gagliardini R; Baldin G; Ciccullo A; Moschese D; Emiliozzi A; Belmonti S; Lamonica S; Montagnani F; Visconti E; De Luca A; Di Giambenedetto S
BMC Infect Dis; 2019 Jan; 19(1):59. PubMed ID: 30654739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
